Immudex
Liselotte Brix is the Chief Scientific Officer at Immudex, where Liselotte has been since July 2009. Prior to this role, Liselotte worked as a Team Leader and Research Scientist at Dako A/S from 2005 to 2009. Liselotte also has experience as an Assistant Professor at The Danish University of Pharmaceutical Sciences and as a PhD student at the same institution. Liselotte holds a Doctor of Philosophy in Immunology and Biotechnology from the Danish Pharmaceutical University, and a Master's degree in Human Biology from the University of Copenhagen. Liselotte's expertise lies in heading Research and Development, IP, and Regulatory Affairs.
This person is not in any teams
Immudex
Immudex is a pioneering life science company spearheading the global adoption of precision immune monitoring. Since 2009, Immudex has been striving to provide researchers worldwide with reliable tools to monitor the cellular immune response accurately. Our goal is to utilize the complex actions and interactions of the immune system to help researchers better understand the causes, accelerate the diagnosis, and more accurately predict the prognosis of diseases. To that end, Immudex markets prime Dextramer® and dCODE® (DNA-barcoded) MHC multimer technologies that grant researchers and clinicians detailed insights into disease-specific immunity resolved to antigen-specific cell populations and single cells. Additionally, Immudex is mandated by the CIC and CIMT to coordinate yearly evaluations of T-cell immune monitoring proficiency and drive the generation of high-quality data that advance immunotherapies. Research, development, and commercial activities are headquartered in Copenhagen, Denmark, with operations in North America out of Fairfax, Virginia. Find out more at www.immudex.com.